sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
spike
protein
major
target
neutral
antibodi
retrovir
sarscov
pseudotyp
construct
use
develop
vitro
microneutr
assay
sensit
specif
sarscov
neutral
antibodi
neutral
titer
measur
assay
highli
correl
measur
assay
use
replicationcompet
sarscov
crossneutr
occur
human
sera
known
contain
antibodi
coronaviru
strain
pseudotyp
assay
use
profil
neutral
antibodi
respons
sarscov
sequenti
serum
sampl
taken
confirm
sar
patient
outbreak
hong
kong
show
longlast
immun
recov
patient
pseudotyp
assay
requir
handl
live
sar
viru
use
tool
determin
neutral
titer
natur
infect
preclin
evalu
candid
vaccin
coronaviru
caus
sever
acut
respiratori
syndrom
sarscov
new
human
pathogen
vaccin
may
urgent
requir
new
outbreak
occur
studi
magnitud
longev
neutral
antibodi
respons
natur
infect
help
establish
correl
protect
gener
immun
humor
immunoglobulin
ig
g
igm
iga
respons
sarscov
studi
extens
howev
studi
neutral
antibodi
respons
natur
infect
limit
partial
neutral
assay
must
perform
biosafeti
level
higher
sarscov
genom
encod
structur
protein
spike
membran
envelop
e
nucleocapsid
n
protein
protein
major
surfac
antigen
viru
neutral
antibodi
respons
primarili
direct
protein
monoclon
antibodi
protein
neutral
viru
map
vaccin
hamster
recombin
parainfluenza
viru
vector
buchholz
et
al
found
express
e
n
absenc
induc
neutral
antibodi
respons
preclin
studi
sarscov
vaccin
provid
evid
gener
strong
neutral
antibodi
respons
sarscov
may
protect
sar
infect
retrovir
lentivir
pseudotyp
employ
lieu
replicationcompet
viru
studi
neutral
antibodi
respons
viral
infect
pseudotyp
virus
encod
marker
gene
bear
foreign
viral
envelop
transfer
marker
gene
target
cell
depend
function
envelop
protein
therefor
titer
neutral
antibodi
envelop
measur
reduct
marker
gene
transfer
lentivir
pseudotyp
bear
sarscov
spike
protein
first
describ
simmon
et
al
studi
viral
entri
studi
use
sarscov
pseudotyp
virus
identifi
receptor
examin
viral
tropism
measur
neutral
antibodi
respons
yang
et
al
construct
lentivir
pseudotyp
harbor
e
protein
found
support
viral
entri
target
cell
aim
studi
establish
neutral
antibodi
assay
use
murin
leukemia
viru
mlv
pseudotyp
bear
sarscov
envelop
mlv
sar
profil
neutral
antibodi
respons
sarscov
natur
infect
rel
long
period
cohort
hong
kong
patient
recov
diseas
total
blood
sampl
obtain
patient
femal
year
age
admit
princ
wale
hospit
hong
kong
march
may
studi
patient
fulfil
world
health
organ
criteria
probabl
case
sar
sampl
patient
test
sarscov
revers
transcriptionpolymeras
chain
reaction
rtpcr
studi
previous
describ
patient
posit
result
pneumonia
develop
patient
requir
intens
care
none
patient
die
infect
patient
multipl
sampl
obtain
sequenti
time
cover
acut
convalesc
recov
phase
diseas
studi
approv
princ
wale
hospit
local
institut
ethic
committe
construct
plasmid
pcaggss
harbor
fulllength
sarscov
urbani
strain
describ
previous
mlv
gagpol
construct
pcmvi
green
fluoresc
protein
gfp
report
construct
pcncg
describ
vesicular
stomat
viru
envelop
protein
vsvg
express
vector
pmdg
describ
previous
hiv
construct
use
describ
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
glutamax
high
glucos
gibco
paisley
scotland
uk
supplement
fetal
calf
serum
penicillinstreptomycin
make
quail
cell
line
gene
encod
receptor
sarscov
human
angiotensinconvert
enzym
clone
human
primari
kidney
cdna
librari
invitrogen
paisley
scotland
uk
use
primer
design
start
stop
subclon
cell
transfect
use
lipofectamin
select
bulk
popul
grown
confluent
plate
cell
split
day
transfect
plate
cell
transfect
gagpol
construct
enhanc
gfp
report
construct
envelopeexpress
construct
use
transfect
reagent
supernat
harvest
h
h
posttransfect
filter
filter
store
mlv
hiv
vector
titer
measur
cell
present
infecti
unit
iu
per
millilit
briefli
cell
infect
vector
egfp
titer
determin
h
later
fluorescenceactiv
cell
sorter
fac
patient
serum
sampl
heat
inactiv
min
serial
dilut
cultur
medium
fifti
pfu
sar
frankfurt
strain
ad
serum
dilut
incub
h
ad
h
vero
cell
per
well
viru
serum
mix
mixtur
incub
plate
day
neutral
assess
cytopath
effect
cpe
neutral
endpoint
taken
last
well
complet
neutral
observ
serum
sampl
assay
duplic
posit
result
confirm
separ
assay
patient
serum
sampl
heat
inactiv
min
serial
dilut
cultur
medium
mix
mlv
sar
virion
iu
volvol
ratio
incub
h
dilut
ad
cell
seed
h
cell
per
well
flatbottom
tissu
cultur
plate
seed
h
previous
gfpposit
cell
count
h
later
fluoresc
microscopi
neutral
antibodi
titer
present
geometr
mean
titer
assay
perform
triplic
retrovir
particl
pseudotyp
sarscov
made
cotransfect
sexpress
plasmid
pcaggss
plasmid
encod
mlv
hiv
gagpol
gfp
vector
genom
cell
cultur
supernat
use
infect
human
quail
cell
line
vsvg
pseudotyp
mlv
particl
mlv
vsv
hiv
particl
hiv
vsv
use
control
mlv
vsv
hiv
vsv
pseudotyp
infect
cell
line
test
mlv
sar
hiv
sar
pseudotyp
infect
low
level
endogen
express
cell
figur
highest
titer
h
iuml
obtain
combin
cell
mlv
sar
system
employ
subsequ
assay
blind
panel
sampl
compris
sera
healthi
person
patient
infect
human
coronavirus
patient
infect
influenza
viru
person
convalesc
sar
provid
health
protect
agenc
hpa
unit
kingdom
valid
pseudotyp
neutral
assay
sampl
posit
assay
inhibitori
concentr
ic
ic
pseudotyp
neutral
titer
compar
titer
obtain
hpa
neutral
assay
use
replicationcompet
sarscov
logarithm
plot
pseudotyp
versu
live
viru
neutral
titer
shown
figur
correl
coeffici
pseudotyp
ic
ic
titer
versu
live
sarscov
neutral
titer
respect
mlv
sar
entri
cell
substanti
inhibit
sera
healthi
person
person
human
coronaviru
antibodi
mlv
vsv
infect
inhibit
sera
data
shown
pseudotyp
assay
thu
shown
sensit
specif
sarscov
neutral
antibodi
evid
crossreact
human
coronavirus
although
live
viru
assay
base
frankfurt
sarscov
isol
pseudotyp
assay
base
urbani
isol
gave
equival
titer
includ
analysi
serum
person
frankfurt
isol
made
blood
sampl
hong
kong
cohort
patient
test
neutral
antibodi
sarscov
protein
use
pseudotyp
neutral
assay
figur
show
number
patient
posit
neutral
antibodi
mean
neutral
antibodi
titer
display
week
onset
fever
sampl
taken
convalesc
recov
phase
day
follow
onset
fever
group
longer
time
block
day
day
day
first
week
onset
fever
patient
sampl
test
neg
neutral
antibodi
appear
neutral
antibodi
first
seen
week
patient
becom
posit
geometr
mean
ic
neutral
antibodi
titer
rang
neg
week
patient
posit
neutral
antibodi
titer
ic
titer
peak
week
mean
titer
persist
patient
day
onset
fever
figur
show
longitudin
profil
neutral
antibodi
respons
sarscov
repres
patient
serial
collect
blood
sampl
avail
test
develop
retrovir
pseudotypebas
assay
facilit
accur
determin
neutral
antibodi
respons
sarscov
without
use
replicationcompet
viru
sinc
neutral
titer
measur
replicationcompet
sarscov
pseudotyp
highli
correl
assay
wide
appli
routin
diagnost
use
preclin
evalu
candid
vaccin
immun
therapi
sar
without
pathogen
handl
advantag
import
nosocomi
infect
arisen
laboratori
handl
sarscov
taiwan
singapor
beij
lack
good
quantit
assay
sarscov
replic
vitro
also
make
pseudotyp
assay
easili
interchang
report
gene
flexibl
platform
studi
neutral
cell
tropism
assay
detect
neutral
antibodi
gener
acut
convalesc
phase
sar
infect
look
neutral
antibodi
respons
previou
research
predominantli
test
sampl
taken
convalesc
phase
diseas
wherea
found
period
day
onset
fever
patient
cohort
neutral
respons
sar
protein
viral
load
measur
realtim
rtpcr
patient
cohort
previous
shown
peak
approxim
day
onset
fever
decreas
bare
detect
around
time
seroconvers
suggest
neutral
antibodi
respons
may
play
role
viral
clearanc
find
implic
diagnost
surveil
sinc
posit
diagnos
neutral
antibodi
made
earlier
infect
complement
test
igg
respons
enzymelink
immunosorb
assay
sar
yet
manifest
season
epidem
threat
like
influenza
make
mass
vaccin
unlik
scenario
rapid
detect
neutral
antibodi
seen
studi
suggest
local
vaccin
effect
vaccin
like
help
control
spread
sarscov
outbreak
vaccin
elicit
rapid
respons
live
viru
articl
also
report
longitudin
neutral
antibodi
profil
patient
sar
use
blood
sampl
collect
serial
time
point
day
broad
spectrum
longitudin
profil
seen
patient
neutral
antibodi
level
persist
mani
recov
person
sever
month
figur
patient
find
complet
loss
neutral
antibodi
titer
sharp
rise
began
end
acut
phase
day
second
patient
ic
neutral
antibodi
titer
attain
day
onset
fever
follow
declin
howev
anoth
patient
neutral
antibodi
detect
day
onset
fever
mainten
neutral
antibodi
titer
import
implic
vaccin
design
gao
et
al
test
rhesu
macaqu
adenovir
vaccin
made
spike
fragment
n
test
show
strong
neutral
antibodi
respons
gener
appear
earli
vaccin
shown
patient
convalesc
sar
similar
respons
full
recoveri
suggest
level
vaccineinduc
neutral
antibodi
may
protect
initi
preclin
studi
mice
hamster
encourag
show
neutral
antibodi
suffici
protect
live
viru
challeng
candid
vaccin
sar
must
move
preclin
evalu
phase
clinic
trial
human
volunt
rapidli
possibl
sinc
possibl
sar
outbreak
uncertain
method
use
analyz
natur
infect
appli
clinic
trial
candid
vaccin
expect
test
equal
applic
anim
sera
